Strs Ohio Allakos Inc. Transaction History

Strs Ohio

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$2.6 - $6.14 $92,300 - $217,970	-35,500 Closed	0 $0
Q1 2022 Apr 21, 2022	BUY	$5.08 - $9.81 $141,224 - $272,718	27,800 Added 361.04%	35,500 $202,000
Q4 2021 Jan 24, 2022	SELL	$8.55 - $111.89 $3,420 - $44,756	-400 Reduced 4.94%	7,700 $75,000
Q3 2021 Oct 22, 2021	SELL	$76.53 - $110.43 $53,571 - $77,301	-700 Reduced 7.95%	8,100 $857,000
Q2 2021 Jul 26, 2021	BUY	$85.37 - $114.1 $34,148 - $45,640	400 Added 4.76%	8,800 $751,000
Q1 2021 Apr 23, 2021	BUY	$109.73 - $153.66 $142,649 - $199,758	1,300 Added 18.31%	8,400 $964,000
Q4 2020 Jan 25, 2021	BUY	$79.58 - $152.45 $525,228 - $1.01 Million	6,600 Added 1320.0%	7,100 $994,000
Q2 2020 Jul 23, 2020	BUY	$44.04 - $80.69 $22,020 - $40,345	500 New	500 $35,000
Q1 2020 Apr 23, 2020	SELL	$44.49 - $93.39 $44,490 - $93,390	-1,000 Closed	0 $0
Q4 2019 Jan 24, 2020	BUY	$66.49 - $137.73 $66,490 - $137,730	1,000 New	1,000 $95,000
Q1 2019 Apr 19, 2019	SELL	$33.79 - $51.99 $81,096 - $124,776	-2,400 Closed	0 $0
Q3 2018 Oct 19, 2018	BUY	$31.25 - $47.64 $75,000 - $114,336	2,400 New	2,400 $107,000

66.9M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $22.9M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.